RNA干扰
基因沉默
计算生物学
生物
基因
核糖核酸
遗传学
作者
Ryan L. Setten,John J. Rossi,Si‐ping Han
标识
DOI:10.1038/s41573-019-0017-4
摘要
The RNA interference (RNAi) pathway regulates mRNA stability and translation in nearly all human cells. Small double-stranded RNA molecules can efficiently trigger RNAi silencing of specific genes, but their therapeutic use has faced numerous challenges involving safety and potency. However, August 2018 marked a new era for the field, with the US Food and Drug Administration approving patisiran, the first RNAi-based drug. In this Review, we discuss key advances in the design and development of RNAi drugs leading up to this landmark achievement, the state of the current clinical pipeline and prospects for future advances, including novel RNAi pathway agents utilizing mechanisms beyond post-translational RNAi silencing.
科研通智能强力驱动
Strongly Powered by AbleSci AI